Just as the understanding of VEGF unlocked an effective therapy for wet AMD, so the better understanding of the pathophysiology of various ocular inflammatory diseases is now opening them up to more targeted therapies, which have the potential to be effective and safer than current, usually corticosteroid-based, regimens. This evidence concerns the gene VEGFA and wet macular degeneration.